News & Filings
SUNPHARMA \u2014 Recent Activity
13 items in the last 14 days
Why Organon (OGN) Drew Buyout Buzz After a Sharp Repricing
Organon & Co. (NYSE:OGN) is one of the 12 Takeover Rumors Targeted by Short Sellers. Organon & Co. (NYSE:OGN) is one of the takeover rumors targeted by short sellers. On April 10, 2026, Organon shares surged after reports said Sun Pharmaceutical Industries was preparing a binding bid for the company, with the potential transaction valued […]
Click to open →
Outcome of Postal Ballot dated 17 March 2026
Click to open →
Why Organon (OGN) Is Surging as Buyout Interest Gains Traction
Organon & Co. (NYSE:OGN) is one of the 10 potential takeover targets with strong price momentum. Around April 10–13, 2026, reports emerged that Sun Pharmaceutical Industries had submitted a binding offer to acquire the company in a deal valued at roughly $10 billion to $12 billion. The market reaction was immediate. Organon shares surged about […]
Click to open →
Organon (OGN) Climbs 39% on $12-Billion Merger Buzz
Organon & Co. (NYSE:OGN) is one of the 10 Stocks Powering Portfolios by Double Digits. Organon surged by 38.8 percent week-on-week, as investors gobbled up shares following reports that it is set to be acquired by Sun Pharmaceutical Industries for $12 billion. According to a report by India-based The Economic Times, Sun Pharmaceutical submitted an […]
Click to open →
This Women’s Health Company Is Drawing Takeover Interest. The Stock Is Soaring.
Organon stock jumped after a report said Sun Pharmaceutical Industries is nearing an all-cash deal for the women’s health company.
Click to open →
Organon Jumps 25% As Report Cites $12 Billion Sun Pharma Offer
Report says Sun Pharmaceutical Industries submitted a binding all-cash bid for Organon, driving shares to their largest gain on record.
Click to open →
Rumour Verification
Click to open →
This Women’s Healthcare Stock Is Up 15% on Reports of a Takeover In the Works
Organon shares surged Friday following reports India’s Sun Pharmaceutical made a bid for the women's healthcare company.
Click to open →
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting ....
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting "Sun Pharma slips nearly 4% after $12 billion Organon deal enters final stage.".<BR><BR>The reply is awaited.
India Opened the Floodgates on Weight-Loss Generics
Indian pharma companies are releasing over 50 generic versions of Ozempic and Wegovy at eye-watering prices of $14 a month.
Click to open →
Biofrontera Inc. Q4 2025 Earnings Call Summary
Moby summary of Biofrontera Inc.'s Q4 2025 earnings call
Click to open →
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
By Rishika Sadam HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week,
Click to open →
India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs
Novo Nordisk's semaglutide patent expires March 20 as Indian drugmakers prepare lower-cost versions and hospitals expand obesity clinics.
Click to open →
Get alerts for important filings
Add SUNPHARMA to your watchlist for board meeting & dividend alerts.
Open analysis →News from yfinance + BSE corporate announcements. Importance scoring is automated. YieldIQ is not registered with SEBI as an investment adviser.